A longitudinal analysis of antihypertensive drug interactions in a Medicaid population

American Journal of Hypertension

Volumn 17, Issue 5, 2004, Pages 421-427

  Carter, Barry L ^a,b   Lund, Brian C ^c   Hayase, Nobumasa ^d   Chrischilles, Elizabeth ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Laureate Psychiatric Clinic and Hospital   (United States)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Antihypertensives; Computer programs; Drug interactions

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANETHIDINE; GUANFACINE; LOOP DIURETIC AGENT; METHYLDOPA; POTASSIUM SPARING DIURETIC AGENT; RESERPINE; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; DATA BASE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; PHARMACIST; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHARMACEUTICAL SERVICES; PREVALENCE; SODIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1942436808     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.01.007     Document Type: Article

References (20)

1. Kelly W.N. Potential risks and prevention, part 1 fatal adverse drug events. Am J Health-Syst Pharm. 58:2001;1317-1324.
2. Kelly W.N. Potential risks and prevention, part 2 drug-induced permanent disabilities. Am J Health-Syst Pharm. 58:2001;1325-1329.
3. Marcellino K., Kelly W.N. Potential risks and prevention, part 3 drug-induced threats to life. Am J Health-Syst Pharm. 58:2001;1399-1405.
4. Kelly W.N. Potential risks and prevention, part 4 reports of significant adverse drug events. Am J Health-Syst Pharm. 58:2001;1406-1412.
5. Chrischilles E.A., Segar E.T., Wallace R.B. Self-reported adverse drug reactions and related resource use. A study of community-dwelling persons 65 years of age and older. Ann Intern Med. 117:1992;634-640.
6. Carter B.L., Lund B.C., Hayase N., Chrischilles E. The extent of potential antihypertensive drug interactions in a Medicaid population. Am J Hypertens. 15:2002;953-957.
7. Hanlon J.T., Weinberger M., Samsa G.P., Schmader K.E., Uttech K.M., Lewis I.K., Cowper P.A., Landsman P.B., Cohen H.J., Feussner J.R. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 100:1996;428-437.
8. Kohn L.T., Corrigan J.M., Donaldson M.S. To Err Is Human Building a Safer Health System. Institute of Medicine Committee on Quality of Healthcare in America. 1999;National Academy Press, Washington, DC.
9. Johnson J.A., Bootman J.L. Drug-related morbidity and mortality a cost-of-illness model. Arch Intern Med. 155:1995;1949-1956.
10. Ernst F.R., Grizzle A.J. Drug-related morbidity and mortality updating the cost-of-illness model. J Am Pharm Assoc. 41:2001;192-199.
11. Carter B.L., Zillich A.J., Elliott W.J. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens. 5:2003;31-37.
12. McKenney J.M., Slining J.M., Henderson H.R., Devins D., Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation. 48:1973;1104-1111.
13. Carter B.L., Barnette D.J., Chrischilles E., Mazzotti G.J., Asali Z.J. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy. 17:1997;1274-1285.
14. Monson R., Bond C.A., Schuna A. Role of the clinical pharmacist in improving drug therapy. Clinical pharmacists in outpatient therapy. Arch Intern Med. 141:1981;1441-1444.
15. Bond C.A., Monson R. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med. 144:1984;1159-1162.
16. Chrischilles EA, Carter BL, Lund BC, Rubenstein LM, Chen-Hardee SS, Voelker, MD, Park TR, Kuehl AK: Evaluation of the Iowa Medicaid Pharmaceutical Case Management Program. J Am Pharm Assoc (in press)
17. Carter B.L., Chrischilles E.A., Scholz D., Hayase N., Bell N. Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management Program. J Am Pharm Assoc. 43:2003;24-33.
18. Lund B.C., Chrischilles E.A., Carter B.L., Ernst M.E., Perry P.J. Development of a computer algorithm for defining an active drug list using an automated pharmacy database. J Clin Epidemiol. 56:2003;802-806.
19. Tatro DS (ed): Drug Interaction Facts. St. Louis, Facts & Comparisons, 2001
20. Multum trusted health information. Available at: www.multum.com. Accessed September 2001